✦ LIBER ✦

Potential Role of Mycophenolate Mofetil in the Management of Neuroblastoma Patients

✍ Scribed by E. Messina; L. Barile; F. Lupi; A. Giacomello

Publisher: John Wiley and Sons
Year: 2005
Weight: 8 KB
Volume: 36
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200512233

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of mycophenolic acid in

Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil

✍ Ashok Jain; Raman Venkataramanan; Tai Kwong; Ravi Mohanka; Mark Orloff; Peter Ab 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

The bioavailability of mycophenolic acid (MPA) after oral administration of mycophenolate mofetil (MMF) has been reported to be more than 90% in healthy volunteers, and in kidney and thoracic organ transplant patients. Such information is limited in liver transplant (LTx) patients. The present study

Effect of T-tube clamping on the pharmac

Effect of T-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil

✍ Jain, Ashokkumar B. ;Hamad, Imad ;Zuckerman, Sheila ;Zhang, Shimin ;Warty, Vijay 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 116 KB 👁 1 views

The aim of the study was to evaluate the effect of t-tube clamping on the pharmacokinetics of mycophenolic acid (MPA) after oral administration of mycophenolate mofetil (MMF) in primary liver transplant recipients treated with tacrolimus as the primary immunosuppressive drug. We evaluated the pharma

ChemInform Abstract: Spectrum of Histolo

ChemInform Abstract: Spectrum of Histologic Changes in Colonic Biopsies in Patients Treated with Mycophenolate Mofetil

✍ Megan K. Selbst; William A. Ahrens; Marie E. Robert; Amy Friedman; Deborah D. Pr 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 15 KB 👁 1 views

Mycophenolate mofetil for remission main

Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis

✍ Langford, Carol A. ;Talar-Williams, Cheryl ;Sneller, Michael C. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Objective: To examine the safety of mycophenolate mofetil (mmf) for remission maintenance in patients with wegener's granulomatosis (wg) who had been treated with daily cyclophosphamide (cyc) and glucocorticoids to induce remission. ## Methods: Fourteen patients were treated for active wg usin

Mycophenolate mofetil in the therapy of

Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome

✍ C. Schneider; R. Gold; M. Schäfers; K.V. Toyka 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB

## Abstract Mycophenolate mofetil 1.5 g daily (30 mg/kg body weight) was given to a patient with ankylosing spondylitis, ulcerative colitis, and severe refractory polymyositis after conventional treatment regimes had failed. No severe side effects occurred. Considerable improvement of clinical symp

Optimization of the dosing regimen of my

Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients

✍ Caroline Barau; Aurélie Barrail-Tran; Bogdan Hemerziu; Dalila Habes; Anne-Marie 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 247 KB 👁 1 views

Mycophenolate mofetil (MMF) is now commonly used in pediatric liver transplant recipients, but no clear recommendations about the dosing regimen have been made for this population. The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an